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Objective
We analyzed the clinical manifestations of Pediatric
Behcet disease (PED-BD) in Turkey. We also evaluated
the correlation between the physician’s global assess-
ment of disease activity (PGA) and Behçet’sS y n d r o m e
Activity Scale (BSAS) which is one of the activity indices
in our cohort.
Method
8 University hospitals in Turkey enrolled children with a
clinical diagnosis of PED-BD. We examined chronologi-
cally the onset of individual symptoms in each patient.
As an activity index we used BSAS which have been
developed to assess the activity specifically for BD in
adults. Correlation between the PGA, and BSAS was
determined.
Results
In 54 patients the mean age at the first symptom was
117.50±45.20 months. BD was suspected at a mean age
of 143.56±39.63 months. The mean delay between the
first symptom and BD suspicion was 27.36±27.15
months. The most common manifestations were oral
ulcer 96.3% (n=52), uveitis 46.3% (n=25), genital ulcer
37% (n=20), pustuler lesion 37% (n=20), erythema nodo-
sum 24.1%(n=13) respectively. Bilateral uveitis was
found in 27.8% (n=15) patients. Pathergy phenomen was
positive in 37% (n=20) patients. Family history of BD
was present in 38.9% (n=21) patients. HLA-B51 carrier
rate was 53.7% (n=29). BSAS was assessed for the 52
patients in our cohort and a moderate correlation
between the BSAS and PGA was demonstrated (r=0.305,
p=0.025).
Conclusion
Our study indicates that BSAS may be a beneficial and
practical index to define the disease activity in PED-BD
and that further studies with a large cohort are required.
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